http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6410297-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bde28565d28f037e78bf4a67776ee24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4741 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 |
| filingDate | 2011-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_209d24c51baa09c725cbd0a1a6f08bcd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3ae5ab46694fc2d48afac766882e579 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e18ab42382291510a4416bacce8be33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3edf09d83dd480e542e4f55ae0f06d2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a92c4b4b4ead00a12e9e2c4ad00c9e39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d94f4814ef02d5431a14c211071834e2 |
| publicationDate | 2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6410297-A2 |
| titleOfInvention | TREATMENT OF DISORDER-RELATED DISORDERS |
| abstract | The compounds of the present invention contain two chiral centers (indicated with * in the formula below) The compounds of the invention may exist in two different diastereomeric forms, the cis- and trans- isomers, which may exist in two enatiomeric forms. The present invention relates only to the trans racemate and the (4aR, 10aR) -enantiomer.Therefore, it is expected that the compounds identified above can be used to treat dyskinesias and other movement related disorders such as Huntington's chorea. Moreover, the present invention contemplates the use of the corresponding trans racemic mixture. The present invention further provides methods for the treatment of Parkinson's disease with a low profile of induction of dyskinesia comprising administering a therapeutically effective amount of said compound. In one aspect, the treatment of Parkinson's disease is as effective as the treatment of L-DOPA. Methods for reversing dyskinesias or for treating Parkinson's disease comprising administering said compound and pharmaceutical compositions thereof are additionally provided. |
| priorityDate | 2009-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6047 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492817 |
Total number of triples: 25.